Literature DB >> 18795715

Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer.

Ivo Novotný1, Petr Dítĕ, Milan Dastych, Anna Záková, Jan Trna, H Novotná, H Nechutová.   

Abstract

BACKGROUND/AIMS: This study addresses the possibility of very difficult differential diagnosis of pancreatic cancer and chronic pancreatitis, especially in cases where pancreatic cancer appears in the course of chronic pancreatitis. A combination of graphical methods and pancreatic biopsy targeted with endosonography seems to be the most precise diagnostic technique. Even negative findings for this procedure cannot exclude the risk of existing tumor and is additionally an invasive technique. Therefore there are different conditions that have to be fulfilled to allow use of both endoscopic and bioptic instruments (biopsy with biopsy needle). Tumor markers of blood serum are used in the practice, but this use seems to be limited by the sensitivity, which is on the level of 60-70% in average.
METHODOLOGY: The authors examined M2-pyruvate-kinase concentration in their group, which included patients with chronic pancreatitis, different grading of pancreatic cancer as well as patients with pancreatic cancer which appeared in the course of chronic pancreatitis. M2-pyruvate-kinase was used as a marker of tumor hyperplasia as it is present in higher concentration in tumors of gastrointestinal tract.
RESULTS: The authors observed important growth in advanced forms of pancreatic tumor compared to patients with chronic pancreatitis. M2-PK was increased in a similar way in patients with pancreatic cancer in the course of chronic pancreatitis. The results led to the conclusion that evaluation of M2-PK concentration helps differentiating between pancreatic cancer and chronic pancreatitis, especially in cases where morphological changes of the gland have focal character and are imitating pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795715

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines.

Authors:  Yogesh Kumar; Sybille Mazurek; Shiyu Yang; Klaus Failing; Marc Winslet; Barry Fuller; Brian R Davidson
Journal:  Tumour Biol       Date:  2010-02-24

2.  Pyruvate kinase M2 and its evolving role as a prognostic marker in systemic malignancies besides colorectal carcinomas.

Authors:  Shailendra Kapoor
Journal:  Tumour Biol       Date:  2012-10-04

3.  Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures.

Authors:  Udayakumar Navaneethan; Vennisvasanth Lourdusamy; Earl Poptic; Jeffrey P Hammel; Madhusudhan R Sanaka; Mansour A Parsi
Journal:  Dig Dis Sci       Date:  2014-10-25       Impact factor: 3.199

Review 4.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

5.  A functional proteomic method for biomarker discovery.

Authors:  Fred Reynolds; Nivedha Panneer; Christopher M Tutino; Michael Wu; William R Skrabal; Christopher Moskaluk; Kimberly A Kelly
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

Review 6.  The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.

Authors:  Lumir Kunovsky; Pavla Tesarikova; Zdenek Kala; Radek Kroupa; Petr Kysela; Jiri Dolina; Jan Trna
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-14

Review 7.  Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

Authors:  Robert S O'Neill; Alina Stoita
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.